SomaLogic, Inc., a company involved in proteomics technology, is extending its collaborative agreement with Novo Nordisk. As part of the agreement, which now extends into the end of 2025, Novo Nordisk will expand its use of the SomaScan proteomics platform in drug research and development. Novo Nordisk will also use SomaLogic’s SomaSignal tests for investigations into cardiometabolic and other diseases. The extension builds upon an agreement between the two companies, which was announced in 2021...